Eiger Biopharmaceuticals (EIGR) Upgraded by ValuEngine to “Buy”

ValuEngine upgraded shares of Eiger Biopharmaceuticals (NASDAQ:EIGR) from a hold rating to a buy rating in a report published on Friday morning.

Other equities analysts also recently issued research reports about the company. Oppenheimer set a $26.00 price target on Eiger Biopharmaceuticals and gave the company a buy rating in a report on Monday, March 12th. Zacks Investment Research cut Eiger Biopharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, February 20th. Wedbush reduced their price objective on Eiger Biopharmaceuticals from $36.00 to $34.00 and set an outperform rating for the company in a research report on Thursday, March 22nd. Piper Jaffray reissued an overweight rating and issued a $17.00 price objective (down from $35.00) on shares of Eiger Biopharmaceuticals in a research report on Tuesday, January 16th. Finally, Ladenburg Thalmann assumed coverage on Eiger Biopharmaceuticals in a research report on Wednesday, January 3rd. They issued a buy rating and a $32.00 price objective for the company. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $27.25.

How to Become a New Pot Stock Millionaire

Shares of EIGR stock opened at $10.85 on Friday. Eiger Biopharmaceuticals has a 12 month low of $6.10 and a 12 month high of $16.20. The company has a debt-to-equity ratio of 0.58, a quick ratio of 5.85 and a current ratio of 5.85. The company has a market cap of $107.37, a price-to-earnings ratio of -2.23 and a beta of 1.58.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.09). sell-side analysts anticipate that Eiger Biopharmaceuticals will post -4.22 earnings per share for the current fiscal year.

In other news, insider Joanne Quan sold 4,000 shares of the stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $10.00, for a total value of $40,000.00. Following the completion of the sale, the insider now directly owns 4,000 shares of the company’s stock, valued at $40,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 28.80% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the stock. Prosight Management LP bought a new position in Eiger Biopharmaceuticals in the fourth quarter worth $9,469,000. Jennison Associates LLC bought a new position in Eiger Biopharmaceuticals in the fourth quarter worth $8,430,000. Armistice Capital LLC bought a new position in Eiger Biopharmaceuticals in the fourth quarter worth $5,357,000. Stonepine Capital Management LLC bought a new position in Eiger Biopharmaceuticals in the fourth quarter worth $2,093,000. Finally, P.A.W. Capital Corp lifted its position in Eiger Biopharmaceuticals by 25.0% in the fourth quarter. P.A.W. Capital Corp now owns 100,000 shares of the biotechnology company’s stock worth $1,395,000 after purchasing an additional 20,000 shares during the period. 68.96% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.chaffeybreeze.com/2018/04/16/eiger-biopharmaceuticals-eigr-upgraded-by-valuengine-to-buy.html.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply